ARCHIVED: Drug targeting tumor metabolism discovered by MD Anderson¡¯s Institute for Applied Cancer Science enters clinical trial
Â鶹ӳ» MD Anderson Cancer Center¡¯s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759. The study will enroll patients with acute myeloid leukemia (AML) and is supported by a $3.5 million investment from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program?. ?Recent approval from the U.S. Food and Drug Administration...
ARCHIVED: American Lung Association and MD Anderson Announce Effort to Improve Tobacco Cessation Treatment for Medicaid Enrollees
The American Lung Association and Â鶹ӳ» MD Anderson Cancer Center are pleased to announce a new partnership aimed at increasing...
ARCHIVED: Tonya Edwards receives MD Anderson¡¯s highest nursing honor
Tonya Edwards, a clinical nurse in Palliative Care at Â鶹ӳ» MD Anderson Cancer Center, is the recipient of the 2016 Brown...
ARCHIVED: MD Anderson and HISD partner for youth tobacco prevention program
Â鶹ӳ» MD Anderson Cancer Center and the Houston Independent School District (HISD) have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students. A Smoking Prevention Interactive Experience (ASPIRE) will be made available in English and Spanish through HISD¡¯s online learning and teaching platform...
ARCHIVED: MD Anderson study identifies significant cost differences between breast cancer chemotherapy regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new...
ARCHIVED: MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer
In a randomized, Phase III trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center, ribociclib, in combination with...
ARCHIVED: Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients
All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor...